Rasagiline
- Generic Name
- Rasagiline
- Brand Names
- Azilect, Rasagiline Mylan, Rasagiline ratiopharm
- Drug Type
- Small Molecule
- Chemical Formula
- C12H13N
- CAS Number
- 136236-51-6
- Unique Ingredient Identifier
- 003N66TS6T
- Background
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
- Indication
For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
- Associated Conditions
- Parkinson's Disease (PD)
- Associated Therapies
- -
Rasagiline and Apathy in Parkinson's Disease
- Conditions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2015-08-10
- Target Recruit Count
- 40
- Registration Number
- NCT00755027
- Locations
- 🇪🇸
Fundacio de Gestio Sanitaria de l'Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2008-06-12
- Lead Sponsor
- Istanbul University
- Target Recruit Count
- 40
- Registration Number
- NCT00696215
- Locations
- 🇹🇷
Marmara University, Istanbul, Turkey
🇹🇷Raif Cakmur, Izmir, Turkey
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
- Conditions
- First Posted Date
- 2005-02-25
- Last Posted Date
- 2009-07-15
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 376
- Registration Number
- NCT00104273
- Locations
- 🇺🇸
Fort Wayne Neurological Center, Fort Wayne, Indiana, United States
🇺🇸Four Rivers Clinical Research, Paducah, Kentucky, United States
🇺🇸Northern Michigan Neurology, Traverse City, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.